Inventor
HOSTETTER DANIEL ROBERT
US18 patents
⚠️ This page may combine multiple inventors who share the name “HOSTETTER DANIEL ROBERT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CYTOMX THERAPEUTICS INC
16 patentsUS10336824B2Jul 2, 2019
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
CYTOMX THERAPEUTICS INC16 citations93
US10138272B2Nov 27, 2018
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CYTOMX THERAPEUTICS INC31 citations93
US9487590B2Nov 8, 2016
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CYTOMX THERAPEUTICS INC15 citations92
US10669337B2Jun 2, 2020
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
CYTOMX THERAPEUTICS INC31 citations89
US11046759B2Jun 29, 2021
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC4 citations84
US11028126B2Jun 8, 2021
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CYTOMX THERAPEUTICS INC8 citations83
US10669339B2Jun 2, 2020
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC10 citations83
US11161906B2Nov 2, 2021
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CYTOMX THERAPEUTICS INC12 citations82
US11174316B2Nov 16, 2021
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC1 citations72
US10611845B2Apr 7, 2020
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CYTOMX THERAPEUTICS INC2 citations72
US12459999B2Nov 4, 2025
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11884746B2Jan 30, 2024
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11548944B2Jan 10, 2023
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11548943B2Jan 10, 2023
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11472875B1Oct 18, 2022
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11802158B2Oct 31, 2023
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
CYTOMX THERAPEUTICS INC1 citations58
UNIV CALIFORNIA
2 patentsUS9255155B2Feb 9, 2016
Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
UNIV CALIFORNIA1 citations58
US10239954B2Mar 26, 2019
Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer
UNIV CALIFORNIA0 citations48